Eli Lilly

Vivus Reports Postive Study Results For ED Drug

By By Val Brickates Kennedy| MarketWatch Pulse| Markets

… avanafil can effectively compete in the oral ED therapy market," Wilson added. Other PDE5 inhibitors for ED include Eli Lilly & Co.'s Cialis, Pfizer Inc.'s Viagra, and GlaxoSmithKline plc's Levitra. Copyright © 2009 MarketWatch, Inc …

Story|11/18/2009

Eli Lilly Adds New Head of Research

By By Darryl R. Isherwood| FOXBusiness| Markets

… By Darryl R. Isherwood FOXBusiness Eli Lilly and Co. (LLY) has poached Jan Lundberg, AstraZeneca Plc ..... from stable to negative to reflect “uncertainty of Eli Lilly ’s ability to counter its exposure to key drug patent …

Story|11/13/2009

Fitch Cuts Its Outlook On Eli Lilly To Negative

By By MarketWatch| MarketWatch Pulse| Markets

… Fitch Ratings has changed its rating outlook Friday on Eli Lilly & Co. to negative from stable, which applies to about ..... debt. Fitch said the move reflects its "uncertainty of Eli Lilly 's ability to counter its exposure to key drug patent …

Story|11/13/2009

Mixed Results For Amgen’s Latest Vectibix Trial

FOXBusiness| Markets

… approximately 40% of colon cancer patients. Vectibix’s main competitor in the space is Erbitux, which is sold by Eli Lilly (LLY) and Bristol-Myers Squibb (BMY). Last year, Erbitux sales rose 8% to $739 million, while Vectibix sales …

Story|11/05/2009

Laying on Bets at America's Biggest Pension Fund

Reuters| Markets

… corporate governance laggards with a Focus List that commands considerable attention. Targets have ranged from drug company Eli Lilly & Co to chairmaker La-Z-Boy. Calpers argues that singling out corporate inadequacies leads to better stock performance …

Story|10/23/2009

GE and Lilly Announce Cancer Breakthrough

By Darryl R. Isherwood| FOXBusiness| Markets

… Darryl R. Isherwood FOXBusiness Scientists at GE Global Research, part of General Electric (GE), and Eli Lilly and Co. (LLY) announced an advancement in cancer research that is a result of the partnership formed in 2007 between the two …

Story|10/21/2009

Eli Lilly Beats the Street on Volume Gains

FOXBusiness| Markets

… FOXBusiness Pharmaceutical company Eli Lilly & Co. (LLY) swung to a profit for its third quarter, a year after getting stung by lawsuits related to its anti-psychotic …

Story|10/21/2009

Eli Lilly Swings To Profit, Boosts Guidance

By William L. Watts| MarketWatch Pulse| Markets

… William L. Watts MarketWatch Pulse LONDON -- Eli Lilly and Co. on Wednesday said it swung to a third quarter profit of $941.8 billion, or 86 cents a share, from a loss of $465 …

Story|10/21/2009

Bove Triggers Late Dive on Wall Street

By Ken Sweet| FOXBusiness| Markets

… competitor Goldman Sachs (GS). The pharmaceutical sector will also be in focus today with results out of Amgen (AMGN), Eli Lilly (LLY) and Genzeme (GENZ). In early trading, oil was down more than 1.15% to $78.20 a barrel while gold fell …

Story|10/21/2009

Stocks In Focus For Wednesday

By MarketWatch| MarketWatch| Markets

… projected to post a third-quarter profit of 37 cents a share, according to analysts surveyed by FactSet Research. Eli Lilly and Co. (LLY) is likely to report a third-quarter profit of $1.02 a share, according to analysts surveyed by …

Story|10/20/2009